MicroRNAs in diagnosis and prognosis in cancer: What does the future hold?

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 667-669

  Nana Sinkam, Patrick ^a,b   Croce, Carlo M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; K RAS PROTEIN; MICRORNA; MYC PROTEIN; UVOMORULIN;

ADAPTIVE IMMUNITY; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; EDITORIAL; GENE AMPLIFICATION; GENE CONTROL; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; NEOPLASM; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS;

HUMANS; MICRORNAS; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; PROGNOSIS;

EID: 77951602461     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.57     Document Type: Editorial

References (30)

1. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993).
2. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10(10), 704-714 (2009).
3. Calin GA, Dumitru CD, Shimizu M et al.: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002).
4. Fabbri M, Garzon R, Cimmino A et al.: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA 104(40), 15805-15810 (2007).
5. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P: Modulation of hepatitis C virus RNA abundance by a liver-specifc MicroRNA. Science 309(5740), 1577-1581 (2005).
6. Wang S, Aurora AB, Johnson BA et al.: The endothelial-specifc microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15(2), 261-271 (2008).
7. Liu CG, Spizzo R, Calin GA, Croce CM: Expression profling of microRNA using oligo DNA arrays. Methods 44(1), 22-30 (2008).
8. Jiang J, Lee EJ, Gusev Y, Schmittgen TD: Real-time expression profling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33(17), 5394-5403 (2005).
9. Nygaard S, Jacobsen A, Lindow M et al.: Identifcation and analysis of miRNAs in human breast cancer and teratoma samples using deep sequencing. BMC Med. Genomics 2, 35 (2009).
10. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2), 647-658 (2007).
11. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029-6033 (2005).
12. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283(2), 1026-1033 (2008).
13. Ribas J, Ni X, Haffner M et al.: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 69(18), 7165-7169 (2009).
14. Ma L, Young J, Prabhala H et al.: MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12(3), 247-256 (2010).
15. Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21(9), 1025-1030 (2007).
16. Johnson SM, Grosshans H, Shingara J et al.: RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005).
17. Yanaihara N, Caplen N, Bowman E et al.: Unique microRNA molecular profles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006).
18. Landi MT, Zhao Y, Rotunno M et al.: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16(2), 430-441 (2010).
19. Ji J, Shi J, Budhu A et al.: MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361(15), 1437-1447 (2009).
20. Hu X, Schwarz JK, Lewis JS et al.: A microRNA expression signature for cervical cancer prognosis. Cancer Res. 70(4), 1441-1448 (2010).
21. Lawrie CH, Gal S, Dunlop HM et al.: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141(5), 672-675 (2008).
22. Haussecker D, Kay MA: miR-122 continues to blaze the trail for microRNA therapeutics. Mol. Ther. 18(2), 240-242 (2010).
23. Kota J, Chivukula RR, O'Donnell KA et al.: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005-1017 (2009).
24. Hunter MP, Ismail N, Zhang X et al.: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3(11), E3694 (2008).
25. Mitchell PS, Parkin RK, Kroh EM et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
26. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer (2009) (Epub ahead of print).
27. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112(1), 55-59 (2009).
28. Calin GA, Liu CG, Ferracin M et al.: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12(3), 215-229 (2007).
29. Shen J, Dicioccio R, Odunsi K, Lele SB, Zhao H: Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer 10(1), 47 (2010).
30. Chin LJ, Ratner E, Leng S et al.: A SNP in a let-7 microRNA complementary site in the KRAS 3́ untranslated region increases non-small cell lung cancer risk. Cancer Res. 68(20), 8535-8540 (2008).